Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

Megan H. Pollack(Vanderbilt University), Allison Betof Warner(Memorial Sloan Kettering Cancer Center), Helen Clare Dearden(The University of Sydney), K. Rapazzo(Vanderbilt University), Ian Valentine(Moffitt Cancer Center), Andrew S. Brohl(Moffitt Cancer Center), Kristin Kathleen Ancell(Vanderbilt University), Georgina V. Long(The University of Sydney), Alexander M. Menzies(The University of Sydney), Zeynep Eroglu(Moffitt Cancer Center), Douglas B. Johnson(Vanderbilt University), Alexander N. Shoushtari(Memorial Sloan Kettering Cancer Center)
Annals of Oncology
October 10, 2017
Cited by 389Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis